



**SERES**  
THERAPEUTICS™

## Seres Therapeutics to Participate in Cowen 42nd Annual Health Care Conference

March 3, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 3, 2022-- [Seres Therapeutics, Inc.](#) (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 10:30 a.m. ET.

An audio webcast of the panel discussion will be available under the "Investors and Media" section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

### About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced to reduce the recurrence of *C. difficile* infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients.

For more information, please visit [www.serestherapeutics.com](http://www.serestherapeutics.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220303005110/en/): <https://www.businesswire.com/news/home/20220303005110/en/>

### PR

Kristin Ainsworth  
[kainsworth@serestherapeutics.com](mailto:kainsworth@serestherapeutics.com)

### IR

Carlo Tanzi, Ph.D.  
[ctanzi@serestherapeutics.com](mailto:ctanzi@serestherapeutics.com)

Source: Seres Therapeutics, Inc.